NCT07864948 Extracorporeal Shock Wave Therapy With or Without Kinesiotaping for Plantar Fasciitis
| NCT ID | NCT07864948 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ankara City Hospital Bilkent |
| Condition | Plantar Fasciitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2026-08-27 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2026-08-27 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate and compare the short- and mid-term effects of Extracorporeal Shock Wave Therapy (ESWT) alone versus a combination of ESWT and Kinesio Taping (KT) on pain, foot functionality, and plantar fascia thickness in patients with plantar fasciitis. A total of 48 patients with chronic plantar fasciitis will be included in this prospective, randomized controlled trial and randomly allocated into two groups: the ESWT group and the ESWT + Kinesio Taping group. Primary outcome measures include pain severity assessed via the Visual Analog Scale (VAS) for morning and general pain, foot functionality evaluated using the Foot Function Index (FFI), and plantar fascia thickness measured via ultrasonography. Evaluations will be conducted at baseline, immediately post-treatment, and at the 3-month follow-up.
Eligibility Criteria
Inclusion Criteria: Age between 18 and 65 years Chronic heel pain for at least 3 months Localized pain and tenderness on palpation at the medial aspect of the calcaneal tuberosity with the ankle in full dorsiflexion Pain intensity of 50 mm or greater on the Visual Analog Scale (VAS) during the first step in the morning Ultrasonographic findings typical of plantar fasciitis (proximal plantar fascia thickness greater than 4 mm with alterations in the fibrillar pattern) Willingness to participate in the study and provide written informed consent Exclusion Criteria: Presence of any skin lesions or integrity disruption in the heel region History of inflammatory or rheumatic arthritis History of fracture, trauma, or surgery in the heel region Presence of systemic infection or malignancy Presence of a cardiac pacemaker Local injection into the heel region within the last 6 months, or use of topical or oral non-steroidal anti-inflammatory drugs (NSAIDs) within the last 2 weeks Unwillingness to participate in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07864948 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Plantar Fasciitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07864948 currently recruiting?
Yes, NCT07864948 is actively recruiting participants. Contact the research team at dr.furkancakir@gmail.com for enrollment information.
Where is the NCT07864948 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07864948 clinical trial?
NCT07864948 is sponsored by Ankara City Hospital Bilkent. The trial plans to enroll 48 participants.